Nagoya University researchers found it’s not the complement protein C3 in the blood that matters, but the C3 produced at the tumor — and it helps immunotherapy work.
NICE has backed Eli Lilly’s Onswik, a weekly insulin injection, for type 2 diabetes — cutting jabs by about 85% for patients who struggle with daily dosing, pending final approval.
Beyond hunger, drugs like Ozempic appear to dial down urges for alcohol, nicotine and more — and researchers point to a reward hub called the lateral septum.
Combining an antibody-drug conjugate with the PARP inhibitor olaparib overwhelmed non-small cell lung cancer’s DNA-repair defenses — and roused the immune system — in preclinical models.
In mice, an appetite-neuron protein called OPA1 guarded against overeating fat and obesity — and its loss hit females harder, hinting at more personalized obesity treatment.
The all-stock deal, paired with a $200 million raise, hands Processa a once-daily, brain-penetrating BTK inhibitor targeting food allergy, chronic urticaria and multiple sclerosis.
A USC deep-learning model, trained on nearly 15,000 scans, shows which parts of the brain age fastest — and flags accelerated aging in areas hit early by Alzheimer’s.
Researchers used AI to redesign antibody fragments so they can work inside cells — a long-standing hurdle — and aimed them at the toxic proteins behind Alzheimer’s, Parkinson’s and motor neurone disease.
In mice, the APOE4 variant raised a protein that made neurons smaller and overexcitable long before memory faltered — and dialing that protein back reversed the damage.
The contract-research giant will help move Medigen’s broader enterovirus vaccine toward clinical trials, building on an EV71 shot already approved in Taiwan and Vietnam.
A large study of over 21,000 women found those who used estrogen-only menopausal hormone therapy had less dementia and less Alzheimer’s pathology — but it’s an association, not proof.
The Series B, led by General Atlantic, backs EXPD-101, a once-daily DPP1 inhibitor licensed from Fosun Pharma and now entering a global Phase 2 trial in COPD.